Physician profile
Amanda Cooper
NPI 1952073827
$3,584.87
in general payments reported to CMS, 2019-2025
31 companies · $1,388 in 2025
The $1,388 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $213 · 2023: $1,141 · 2024: $843 · 2025: $1,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,372.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $917.63 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $471.02 | 2022-2025 | Mounjaro, Zepbound |
| Dexcom, INC. | $421.73 | 2022-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $382.09 | 2022-2025 | |
| Novo Nordisk INC | $371.56 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $266.06 | 2023-2025 | Otezla, Repatha, Repatha |
| Corcept Therapeutics | $64.61 | 2024-2025 | Korlym |
| Exact Sciences Corporation | $63.74 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.05 | 2024-2025 | Xifaxan |
| Lundbeck LLC | $51.43 | 2022-2025 | Rexulti |
| Insulet Corporation | $49.58 | 2023 | Omnipod |
| Alnylam Pharmaceuticals INC. | $42.86 | 2022-2023 | Onpattro |
| Xeris Pharmaceuticals, INC. | $41.43 | 2022-2023 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $34.49 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Renalytix Ai, INC. | $34.17 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $32.05 | 2023-2024 | |
| Abbott Laboratories | $28.71 | 2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $24.25 | 2025 | Veozah |
| Pfizer INC. | $23.89 | 2024 | |
| Sumitomo Pharma America, INC. | $22.82 | 2025 | Gemtesa |
| Acadia Pharmaceuticals INC | $20.87 | 2025 | Nuplazid |
| Biohaven Pharmaceutical Holding Company LTD. | $19.36 | 2022 | |
| Sanofi Pasteur INC. | $19.17 | 2025 | |
| Hologic Sales and Service, LLC | $19.15 | 2024 | Thinprep 2000 Processor, Aptima |
| Novartis Pharmaceuticals Corporation | $17.11 | 2023 | |
| Dynavax Technologies Corporation | $16.79 | 2023 | Heplisav-B |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.01 | 2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.77 | 2025 | Caplyta |
| Stryker Corporation | $15.68 | 2025 | Clottriever Bold Catheter |
| Phathom Pharmaceuticals, INC. | $13.90 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $13.89 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.